infection have been attributed to various phenomena [9] , but the mechanism(s) for impaired antipolysaccharide responses remains to be fully defined. It is of note that binding of the B cell superantigen HIV gp120 to heavy-chain variable region (V H ) epitopes of gene segments from the V H 3 immunoglobulin gene family [10] has been associated with reduced expression of V H 3 determinants by antibodies and B cells in HIV-infected persons [11, 12] . In light of reports from our group and others showing that V H 3 gene subgroup members are the predominant genes in antibodies to PPS [13] [14] [15] [16] [17] , we wondered whether decreased V H 3 expression could translate into impaired antibody responses to PPS in HIV-infected persons. Our group previously reported that pneumococcal vaccination elicited increased levels of PPS-specific antibodies expressing certain V H 3 determinants in HIV-uninfected but not in HIV-infected subjects [13] . In the present study, we extended these findings to B cells by using a method that combines the sensitivity of polymerase chain reaction (PCR) with the quantitative capacity of an ELISA (termed a PCR ELISA) [18] [19] [20] to analyze the influence of pneumococcal vaccination on V H gene subgroup expression in HIV-infected and -uninfected subjects.
Materials and Methods
Subjects and pneumococcal vaccination. Ten HIV-uninfected (aged 23-41 years) and 12 HIV-infected (aged 28-56 years) volunteers were vaccinated with 1 intramuscular dose of 23-valent PPS vaccine (Pneumovax; Merck Sharpe & Dohme, Swiftwater, PA), which contains 25 mg/0.5 mL of each of the 23 capsular polysaccharides. The HIV-infected subjects were patients in the Bronx at Montefiore Medical Center (10 subjects) and Jacobi Medical Center (1 subject) and at the Houston VA Medical Center (1 subject). The HIV-infected subjects were recruited over !6 months solely on the basis of not having received a previous pneumococcal vaccination. Age, sex, CD4 lymphocyte count, virus load, antiretroviral regimen, and duration of therapy of the HIV-infected subjects is shown in table 1. Samples from all subjects were studied in a blinded, coded fashion.
Cell preparation, RNA extraction, and cDNA synthesis. Peripheral blood was obtained from each subject before and 7 days after vaccination. Circulating B cells expressing the CD19 receptor (CD19-positive cells) were positively selected from 5-10 mL of whole blood with magnetic beads coated with an antibody to CD19 (Dynal, Oslo). Total RNA was extracted from CD19-positive cells with Trizol reagent (Gibco BRL, Gaithersburg, MD) according to the manufacturer's instructions. DNA was removed by use of RNAase-free DNAase (Gibco BRL), and first-strand cDNA was synthesized with Superscript II reverse transcriptase (Gibco BRL) by use of oligo(dT) as a primer, for 1 h at 37ЊC. cDNA was released by digesting mRNA/cDNA hybrids with RNase and was size purified (500-3000 bp) with the Qiaquick gel extraction kit (Qiagen, Santa Clarita, CA) according to the manufacturer's instructions. The purified cDNAs were poly-dG tailed with dGTP and terminal deoxytransferase (Promega, Madison, WI). Free dGTP was removed by the Quiquick gel extraction kit.
PCR amplification of V H 1-6 cDNA. V H genes were amplified by primary anchored PCR amplification of cDNA, as described elsewhere [20] , in 50 mL of 40 mM Tris-HCl (pH 7.5), 50 mM KCl, 25 mM (NH4) 2 SO 4 , 50% glycerol, 0.1 mM EDTA, 5.0 mM bmercaptoethanol, 0.25% Thesit, 200 mM dNTPs (Clontech Laboratories, Palo Alto, CA), 1 U of Taq polymerase (Clontech), and sense anchor primers (AN and ANC as described in [20] ) and antisense primers corresponding to the 5 end of the human m, a, and g constant region genes. All except the Ca primer were described by Kohsaka et al. [20] . The Ca primers were designed for this study and had the following sequences: Ca1, 5 -GTCACACT-GAGTGGCTCCTGG-3 , and Ca2-biotin, 5 -CGGGAAGAC-CTTGGGGCTGG-3 . All primers were synthesized by the DNA synthesis facility of the Albert Einstein College of Medicine Cancer Center. The PCR reaction was done as follows: 5 min incubation at 94ЊC, followed by 20 cycles of 45 s at 94ЊC, 45 s at 42ЊC, and 1 min at 72ЊC, with a final 7-min extension at 72ЊC. The PCR products were electrophoresed on a 1.2% agarose gel, and DNA fragments of 500-700 bp were purified with the Qiagen kit. Nested PCR amplification was then performed with AN primers and internal antisense primers, which were biotinylated as described elsewhere [20] . The nested PCR reaction was done as follows: 5 min incubation at 94ЊC followed by 25 cycles of 45 s at 94ЊC, 45 s at 55ЊC, and 1 min at 72ЊC, with a final 7-min extension at 72ЊC. The cDNA purified by the Qiagen PCR purification kit was dissolved in Tris-EDTA buffer. b-actin was used as a control to ensure that the PCR was in the linear nonsaturating range for each reaction.
PCR ELISA. A PCR ELISA was used, as described by Rassenti et. al. [19] , to determine the proportion of each V H gene family. In brief, the purified PCR products were diluted to a final volume of 600 mL in 6ϫ standard saline citrate (SSC) and 0.1% Tween 20 and distributed into 6 streptavidin-coated ELISA plate wells (Boehringer Mannheim, Indianapolis). The plates were incubated for 1 h at 37ЊC and washed 3 times with PBS. The cDNA was denatured on the plates with 0.1 N NaOH. The plates were then rinsed once with 0.1ϫ SSC, followed by 2 washes with 6ϫ SSC. After digoxigenin-labeled oligonucleotides corresponding to V H 1-V H 6 were added at a concentration of 0.03 pmol/mL, the plates were incubated for 20 min at 65ЊC and then for 100 min at 42ЊC and were washed 3 times with 6ϫ SSC, 0.1% N-lauroylsacosine, and once with 1% blocking buffer (Boehringer Mannheim) overnight. V H gene family-specific cDNA was detected by an antibody detection kit (Boehringer Mannheim) as follows: 200 mL/well of peroxidaseconjugated anti-digoxigenin antibody in blocking buffer was added to the plates and incubated for 60 min at 37ЊC; the plates were washed once with blocking buffer and 3 times with 0.1 M maleic acid and 0.15 M NaCl, pH 7.5; the substrate 1,3,5-trimethylbenzene was added for 30-60 min in the dark; then 1 M H 2 SO 4 was added to stop the reaction, and the optical density (OD) of the wells was measured at 450 nm with an ELISA plate reader (Dynex; Dynal). Each plate with cDNA derived from donor B cells contained serial dilutions of a positive control (a 120-bp DNA fragment purified from a plasmid and provided by H. Kohsaka, Tokyo Medical and Dental University, containing sequences for each of the 6 oligonucleotide probes representing the V H 1-V H 6 gene families).
Serologic analysis of antibody response to vaccination. The prevaccination and day 28 postvaccination levels of antibodies to PPS were determined in the sera of 7 HIV-uninfected subjects with . The mean CD4 T cell level of the 4 HIV-infected subjects was 149 cells/ mL (range, 57-350 cells/mL). The sera were separated from whole blood samples by centrifugation, heat treated for 30 min at 56ЊC, and stored at Ϫ20ЊC until use. Antibody levels to the PPS in the whole vaccine were determined by ELISA as described elsewhere [13] . In brief, 96-well polystyrene ELISA plates (Costar; Corning Glass Works, Corning, NY) were coated with the whole vaccine (11.4 mg/mL of each PPS). The serum samples were absorbed with 50 mg/mL of purified cell wall polysaccharide (Statens Seruminstitut, Copenhagen) for 1 h at 4ЊC before use. The sera were then applied to the plates in duplicate and were serially titrated in 1% bovine serum albumin in PBS starting at a dilution of 1 : 50. After a wash, the plates were incubated with alkaline phosphataselabeled goat antibodies to human IgA, IgG, or IgM (Southern Biotech, Birmingham, AL). For V H idiotype expression, the plates were incubated at 37ЊC for 1 h with murine monoclonal antibodies (MAbs) that recognize certain V H 3 determinants, namely, MAbs D12, B6, and 16.84, which were used at a concentration of 5 mg/ mL, as described elsewhere [13] . The binding of the MAbs was detected after a wash with goat anti-mouse alkaline phosphatase-labeled antibody (Southern Biotech). After another wash, the plates were developed with p-nitrophenyl phosphate (Sigma, St. Louis) in diethanolamine buffer (pH 9.8). ODs at 405 nm were measured by an ELISA reader (MRX; Dynex Technologies, Chantilly, VA). Negative and positive controls included omitting the serum samples and US standard human antipneumococcal reference serum lot 89SF (courtesy of C. Frasch, Food and Drug Administration, Bethesda, MD), respectively. The mean of duplicate samples was calculated at each dilution after subtracting twice the background. End-point titers calculated from titration curves were used to assess the antibody levels to PPS, as described elsewhere [13] .
Statistical analysis. Comparisons were made of V H family expression on the basis of the PCR ELISA and antibody titers to PPS by Mann-Whitney U test (unpaired comparisons [e.g., between HIV-infected and -uninfected groups]) or the Wilcoxon signed rank test (paired comparisons [e.g., between pre-and postvaccination studies]). Correlations between antibody titers and idiotype expression and antibody titers and V H family expression after vaccination were done by Spearman's correlation test. All tests were done with statistical software (SPSS, Chicago). Significance was set at . P ! .05
Results
Prevaccination repertoires. The prevaccination expression of the HIV-infected and -uninfected subjects is shown in table 2. The repertoires of the HIV-uninfected and -infected subjects were similar for V H 1, V H 3, and V H 4 IgA. The HIV-infected group had greater V H 5 expression than the HIV-uninfected group, versus . For IgG, the HIV-12.3% ‫ע‬ 7.5%
5.5% ‫ע‬ 6.8% Postvaccination repertoires of the HIV-uninfected subjects. Table 3 shows the pre-and postvaccination expression of each V H gene subgroup for the HIV-uninfected subjects. For IgG and IgA, there was a significant postvaccination increase in expression of the V H 3 subgroup, from 46.4% to 67.1% and 51.5% to 73.2%, respectively; for IgG, there was a significant decrease in V H 1 and V H 5 subgroup expression, from 10.7% to 3.7% and 9.3% to 3.3%, respectively. For IgM, 7 of 10 subjects manifested a postvaccination increase in expression of the V H 3 subgroup; 2 were unchanged, and 1 showed a decrease (table  4) . There was no statistically significant difference between preand postvaccination expression of IgM V H 3 for this group (table  3) . Seven of the 10 subjects manifested a postvaccination increase у1 SD from their prevaccination expression of the IgG V H 3 subgroup. Overall, 8 subjects had an increase in 11 V H 3 isotype (table 4) . One subject without an increase in IgG V H 3 had an increase in V H 4 (not shown). Three subjects without an IgM V H 3 increase had increased V H 1 (2 subjects) or V H 4 (2 subjects), and 1 subject without an increase in IgA V H 3 had an increase in V H 4 у1 SD after vaccination (not shown). Statistical comparisons were done by Wilcoxon signed rank test (a nonparametric, paired test).
Postvaccination repertoire of the HIV-infected subjects. Table 5 shows the pre-and postvaccination expression of each of the V H gene subgroups for the HIV-infected group. For IgG, there was a significant postvaccination increase in V H 5 from 1.6% to 9.1%. There was no significant difference between preand postvaccination expression for the IgG V H 1, V H 3, and V H 4 subgroups or for any IgA or IgM V H subgroup. For IgG, no subject had increased postvaccination expression of the V H 3 subgroup that was 11 SD above the prevaccination level, although 1 subject (M5) had a borderline response (table 4) Serology. The isotype and idiotype titers of the PPS-specific antibodies of the HIV-infected subjects were significantly lower than those of the HIV-uninfected subjects. The HIV-uninfected subjects had significant postvaccination increases in anti-PPS IgG, IgM, and IgA ( , Wilcoxon signed rank test; figure P ! .02 1). There was no statistically significant change in the anti-PPS titer for the HIV-infected group (figure 1). There was a postvaccination increase in antibodies expressing the V H 3 determinants recognized by each of the MAbs D12, 16.84, and B6 in the HIV-uninfected subjects only ( , Wilcoxon signed P ! .02 rank test; figure 2 ). The increase in titer for the 4 HIV-infected subjects was not statistically significant. The postvaccination levels of IgG, IgM, and IgA and the D12, 16.84, and B6-expressing antibodies to PPS were significantly greater in the HIVuninfected group than in the HIV-infected group ( , P ! .03 Mann-Whitney U test). Correlation analysis revealed an association between IgM antibody responses and IgM V H 3 expression in the HIV-uninfected group ( , Spearman's cor-P ! .03 relation test).
Discussion
The most striking observation in this study was that HIVuninfected subjects manifested an increase in IgG and IgA V H 3 expression after pneumococcal vaccination that did not occur in HIV-infected subjects. This novel and unexpected finding indicates that a polysaccharide vaccine changed the expressed V H repertoire of the circulating B cell compartment. The proportion of V H 3 subgroup expression differed according to isotype. These results extend to B cells our previous findings that pneumococcal vaccination elicits an increase in serum antibodies to PPS-expressing V H 3 in HIV-uninfected but not HIV-infected subjects [13] . In light of reports from our group and others that the V H gene expression of antibodies to PPS is restricted to members of the V H 3 subgroup [14, 15, 17, 21] , the data presented here suggest an association between the anti-PPS response and the status of the V H 3 repertoire. Thus, reduced expression of certain V H 3 genes in HIV-infected subjects may have translated into an ineffective anti-PPS response. There is a precedent for a link between immunoglobulin repertoire defects and disease susceptibility, namely, that the lightchain allele used in the antibody response to the capsular polysaccharide of Haemophilus influenzae type b is defective in a population that has a significantly increased incidence of infection [22] .
The finding that the HIV-uninfected group in this study, a group representative of the population in which PPS vaccines are most immunogenic [23, 24] , had a postvaccination increase in IgG V H 3 expression suggests that the anti-PPS response may arise in part from the IgG compartment. Although PPS is a Tindependent antigen that is not thought to induce immunologic memory, this is consistent with the proposal that the human anti-PPS response resembles a recall response [15, 25] . Further support for the concept that pneumococcal vaccination induces a secondary response is provided by evidence that memory cells reside in the marginal zone of the spleen [26] , the anatomic region where antibody responses to PPS occur [27, 28] . A possible role for the preimmune IgG repertoire in the anti-PPS response is supported by the reduced preimmune expression of IgG V H 3 in the HIV-infected group and their markedly reduced serologic response to vaccination as compared with the HIVuninfected group. Although a correlation between the magnitude of the B cell and antibody response to PPS has not been demonstrated, V H gene expression is a qualitative parameter that may more accurately predict the success of vaccination.
A correlation between IgM V H 3 expression and IgM titer was found in the HIV-uninfected group: 7 of 10 subjects manifested a postvaccination increase in IgM V H 3 expression. However, vaccination had a different influence on the IgM than on the IgG or IgA repertoire, since the increase in IgM V H 3 expression was not statistically significant. The maximum increase in IgM V H 3 may not have been detected in this study, because the IgM B cell response to PPS is maximal earlier than IgG or IgA, which were maximal at the time our samples were collected [29] . In addition, the size of the cohort may have prevented the detection of a small change in IgM V H 3 expression. The isotype Figure 1 . Pre-and postvaccination antibody titers to polyvalent pneumococcal capsular polysaccharide (PPS). Inverse titer of serum antibodies to PPS in whole pneumococcal vaccine, as determined by ELISA, is shown on y axis for each isotype shown on x axis. Data are mean and SD for prevaccination and day 28 postvaccination sera from 7 human immunodefiency virus (HIV)-uninfected and 4 HIV-infected subjects. Increases in titer for HIV-uninfected, but not infected, subjects were significant ( , Wilcoxon signed rank test). P ! .02 of idiotype-positive antibodies to PPS could not be determined by the serologic technique used in this study. However, in our previous study [13] , a significant proportion of the antibodies to PPS that expressed V H 3 determinants were IgM. Since serotype-specific antibodies to PPS may only use a subset of V H 3 gene segments [14, 15, 17, 21] , vaccination may have induced a shift in the expression of certain V H 3 gene segments within the IgM repertoire of the HIV-uninfected group (e.g., those expressing the determinants recognized by D12, 16.84, and B6) without a significant change in overall V H 3 expression. Changes in the expression of individual V H 3 genes were reported during reconstitution after bone marrow transplantation [30, 31] , but such a phenomenon would not be detected by the PCR ELISA used for our studies or by available serologic techniques. Hence, it may be necessary to analyze individual antigen-specific B cells expressing IgM to gain a better understanding of the impact of vaccination on the IgM repertoire.
The use of V H 3 genes in antibodies to PPS suggests that immunoglobulin receptors encoded by these genes have structural characteristics that permit PPS binding. Although it is not known why selective increases in V H 3-expressing antibodies to PPS [13] and B cells (this study) were observed after pneumococcal vaccination, it is of note that the V H 3 gene subgroup constitutes a distinct clan that has been implicated in antigen binding [32] . Hence, the striking absence of a V H 3 response among the HIV-infected subjects in this study may reflect reduced expression of V H 3-positive B cells with the capacity to bind PPS. However, vaccination did alter the expression of the postvaccination V H repertoire of the HIV-infected group. Unexpectedly, this group manifested a postvaccination increase in IgG V H 5 expression. Notably, the preimmune IgA and IgM V H 5 repertoires of the HIV-infected, but not the HIV-uninfected group, were expanded. To date, V H 5 genes have not been described in antibodies to PPS, although the predominant use of V H 3 genes is well documented (see above). The V H 5 subgroup consists of only 2 genes: 1 is preferentially used in IgE from patients with asthma [33] , and a B cell superantigen/allergen has been implicated in the expanded V H 5 repertoire of allergic patients [34] . Although atopy has been described in HIV-infected patients [35] , this study did not evaluate B cell IgE or serum immunoglobulins. Clearly, it would be useful to determine whether V H 5 is expressed by antibodies to PPS from HIVinfected persons, but serologic reagents to detect the V H 5 subgroup are not available.
It has been proposed that a microbial product, the B cell superantigen gp120, plays a role in mediating aberrant expression of the V H 3 repertoire in HIV-infected persons [10, 12] . In light of the latter and of the increased IgM V H 5 subgroup expression in HIV-infected subjects reported by Bessudo et al. [18] , our finding of vaccine-induced increases in V H subgroups that also bind superantigens suggests that the influence of superantigens on the V H repertoire of HIV-infected persons deserves further evaluation.
The prevaccination repertoires of the HIV-uninfected and Inverse titer of serum antibodies to PPS in whole pneumococcal vaccine that express determinants recognized by each monoclonal antibody shown on x axis is shown on y axis. Titers were determined as described in text. Data are mean and SD for prevaccination and day 28 postvaccination sera from 7 human immunodefiency virus (HIV)-uninfected and 4 HIV-infected subjects. Increases in titer for HIV-uninfected, but not infected, subjects were significant ( , Wilcoxon signed rank test). P ! .02 -infected groups in this study differed. Overall, our data agree with that of Bessudo et al. [18] , since we found differences in V H 3 and V H 5 subgroup expression between HIV-uninfected and -infected subjects. It is not clear whether unstable V H 3 expression is linked to CD4 cell level. One study [11] showed that V H 3 expression was decreased in the setting of CD4 levels !200 cells/mL, but another study showed aberrant V H 3 expression at higher CD4 cell levels [18] . Both studies examined the IgM repertoire, and 1 examined the expression of the determinant recognized by D12, which was also examined in this and our previous study [13] . We used CD19-positive cells and determined IgG, IgA, and IgM V H gene subgroup expression, whereas others used the PCR ELISA used here to analyze the frequency of IgM V H subgroup expression among total peripheral mononuclear cells [18] [19] [20] . We used CD19-positive cells to eliminate plasma cells. The latter may produce a disproportionate amount of immunoglobulin message that may skew the results and obscure the nature of the vaccine-elicited repertoire. Among CD19-positive cells, we found that V H subgroup expression differed according to isotype. Taken together, the results suggest the possibility of a shift in the V H 4 repertoire toward IgG and a possible block in differentiation of the V H 3 repertoire of the HIV-infected group. Although these findings cannot yet be explained, it is of interest that underutilization of V H 3 and preferential use of V H 4 genes has been reported in HIV-associated lymphomas [36] and antibodies to HIV [9] . This suggests that HIV-specific B cells could have contributed to the increased prevaccination expression of IgG V H 4 in the HIVinfected group, although antibodies to HIV were not examined in this study.
Although in 1 study PPS vaccination soon after HIV seroconversion was associated with a better anti-PPS response [37] , most patients are not identified so early. Furthermore, many studies have shown similar responses to PPS vaccines among HIV-infected patients with higher rather than lower CD4 cell levels (reviewed in [1] ), and immunologic correlates of pneumococcal susceptibility and/or the magnitude of PPS antibody responses in the setting of HIV infection have not been convincingly demonstrated [4, 38, 39] . Our data suggest that V H 3 expression might be a useful parameter to assess PPS vaccine responses, although this requires confirmation in larger studies. Our results suggest that alternative immunogens that can elicit antibodies from other V H subsets might be useful for preventing pneumococcal infections in HIV-infected persons. In this regard, it would be helpful to know whether antibodies to PPSexpressing V H 5 can be isolated and if they are biologically functional. However, given the present state of knowledge and available vaccine targets, we believe our data support the reconsideration of antibody-based therapy for pneumococcal therapy and prophylaxis in HIV-infected persons. A precedent for this approach was the landmark study that showed that intravenous immunoglobulin could reduce the incidence of pneumococcal infections in certain HIV-infected children [40] . Serum therapy was the reference standard for the treatment of pneumococcal infections early in the twentieth century [41] , until it was replaced by antibiotics because of the toxicity of heterologous sera in humans. The use of modern reagents, such as human serotype-specific MAbs, can improve the safety and perhaps the efficacy of historical antibody preparations.
We found no evidence that CD4 lymphocyte levels, virus load, or exposure to antiretroviral agents were associated with the serologic or molecular responses to PPS in this or in our prior serologic study [13] , although this assessment may have been limited by the size of our cohort. It seems logical that highly active antiretroviral therapy (HAART) can influence the composition of the B cell repertoire. A decrease in both hypergammaglobulinemia and the frequency of IgG antibodysecreting cells was recently reported in patients receiving HAART [42] . Another group reported increased V H 3 expression among HIV-infected subjects receiving triple combination therapy when compared with untreated subjects [43] . The significance of these reports for the restoration of the anti-PPS response is uncertain. The HIV-infected subjects in this study who received antiretroviral therapy had been treated 1-15 months and manifested CD4 cell levels above their nadir, yet no treated subject had an increased IgG V H 3 response. Since the treated subjects constituted only half of the HIV-infected cohort and since many still had detectable viremia, more work is needed to determine whether HAART will facilitate enhanced anti-PPS responses and restore normal patterns of V H gene expression. Our findings suggest that a mechanism to explain altered HIVassociated V H gene expression may need to be identified, to fully understand mechanisms of PPS vaccine failure and to develop rational approaches for treating and preventing pneumococcal infections in HIV-infected persons.
